Epidiolex in Typical Absence Seizures

Phase 4 Completed 14 enrolled University of South Florida Jazz Pharmaceuticals · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a Pilot study, open-label study consisting of a screening period of up to 4 weeks, a 4-week dose-titration treatment period to dose of up to 20 mg/kg/day BID of CBD (Epidiolex), and a 30 day safety follow-up period following the last dose of study medication.

Timeline

Start: 2021-07-30
Primary completion: 2023-05-27
Completion: 2023-05-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cannabidiol	Other / unclassified	20 mg/kg	—

Indications

No indication recorded.